Non-lipidated Omp Adjuvants for Cellular Immune Response

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current vaccine adjuvants fail to effectively induce strong cellular Th1 and cytotoxic T cell immune responses, which are crucial for preventing viral chronic infections and intracellular pathogen infections, and often cause adverse reactions, while existing mucosal adjuvants face challenges with stability, safety, and efficacy.

Innovation Solution

Development of non-lipidated bacterial outer-membrane polypeptides, such as Omp19S and Omp16S from the Brucella genus, which act as adjuvants to enhance immune responses by promoting Th1-, Th17-, or CTL-type immune responses, and are administered via mucosal or parenteral routes.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Quantity of substance

If aluminum salts or traditional adjuvants are used, then humoral immune response is enhanced, but cellular Th1 and cytotoxic T cell responses are not effectively induced

Engineering Contradiction:

Improveamount of antibody productionVSAvoidcellular immune response induction

Core Design Contradiction:

Quantity of substanceVSReliability

Solution Approach 1:

The patent modifies the chemical composition parameters of adjuvants by using non-lipidated bacterial outer-membrane polypeptides (Omp19S, Omp16S) instead of traditional aluminum salts. This parameter change transforms the adjuvant mechanism from Th2-polarizing to Th1 and CTL response-inducing, while maintaining humoral response enhancement capabilities.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent creates composite vaccine formulations combining non-lipidated Omp polypeptides with antigens. These composite materials exhibit synergistic effects where the Omp adjuvant component specifically induces cellular Th1 and CTL responses while the antigen component stimulates humoral immunity, achieving both immune response types simultaneously.

Inventive Principle:

Principle #40Composite materials

2Reliability

If oil emulsion adjuvants are used to stimulate Th1 response, then cellular immunity is enhanced, but adverse reactions and safety issues occur

Engineering Contradiction:

Improvecellular Th1 immune responseVSAvoidadverse reactions

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent extracts and isolates the beneficial immunostimulatory components (non-lipidated Omp polypeptides) from complete bacterial cells or crude extracts. By taking out only the specific protective antigens and adjuvant components, the patent eliminates harmful bacterial elements while retaining the ability to induce strong Th1 and CTL responses without adverse reactions.

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent uses recombinant Omp polypeptides produced through expression systems as temporary,可控 adjuvants. These purified polypeptide molecules serve their immunostimulatory function and are then metabolized without persisting as foreign materials, avoiding the chronic inflammation and granuloma formation associated with oil emulsion adjuvants.

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

3Reliability

If mucosal adjuvants are used to induce local immune response, then mucosal immunity is enhanced, but stability and safety challenges arise

Engineering Contradiction:

Improvemucosal immune responseVSAvoidadjuvant stability

Core Design Contradiction:

ReliabilityVSStability of the object's composition

Solution Approach 1:

The patent modifies the physical and chemical parameters of mucosal adjuvants by using stable, non-lipidated Omp polypeptides with defined amino acid sequences. These polypeptides maintain structural integrity and immunostimulatory activity across varying pH and temperature conditions in the mucosal environment, overcoming the stability issues of traditional mucosal adjuvants.

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The Omp19S and Omp16S adjuvants induce robust cellular immune responses, including cytokine production and T cell activation, without adverse local reactions, and inhibit antigen degradation, thereby enhancing vaccine efficacy and safety.

Implementation Method 1

The Omp19S and Omp16S adjuvants induce robust cellular immune responses, including cytokine production and T cell activation

Methodology Applied

Scientific EffectCytokine production:

Implementation Method 2

inhibit antigen degradation, thereby enhancing vaccine efficacy and safety

Methodology Applied

Scientific EffectInhibition of degradation:

Data Source

PatentUS9511137B2Adjuvant for vaccines, vaccines that comprise said adjuvant and uses thereof

Publication Date: 2016.12.06 INIS BIOTECH LLC

AI summary

Adjuvant for vaccines that comprises a non-lipidated bacterial outer-membrane polypeptide (Omp), in which the bacteria may be of those of Brucella genus. The adjuvant may be a modified polypeptide or may be, for example, the Omp19S polypeptide or the Omp16S polypeptide, parts or mixtures of the two. In a preferred embodiment, the adjuvant is the non-lipidated polypeptide included in SEQ ID No: 1, or parts thereof. In a further preferred embodiment, the adjuvant is the non-lipidated polypeptide included in SEQ ID No: 2 or parts thereof.